Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
Immunohistochemical techniques using antibodies to prostate specific antigen (PSA) and prostate specific acid phosphatase (PAP) have greatly increased the feasibility of reliable diagnosis of primary or metastatic prostatic carcinoma. A review of the literature showed the diagnostic specificity of antibodies to PSA or PAP to be 100% and 87-100%, respectively. The corresponding figures for diagnostic sensitivity were 94-100% and 90-100%.
D000135:Acid Phosphatase / Q000378:metabolism*; D000230:Adenocarcinoma / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D011467:Prostate / Q000378:metabolism*; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000378:metabolism*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen